Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

COGT vs ZBIO: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

ZBIO Wins Head-to-Head Institutional Verdict (2–1 across 6 Pillars · 3–3 Matrix Metrics)

ZBIO Overall Winner 6-Pillar Tally: COGT 1 – 2 ZBIO (3 Tie) Matrix Metrics: COGT 3 – 3 ZBIO

As of Nov 16, 2026, Zenas BioPharma, Inc. (ZBIO) is the stronger overall head-to-head candidate over Cogent Biosciences, Inc. (COGT) in the Tradestie Institutional Equity Comparison Engine, winning 3–3 core matrix metrics and 2–1 across our 6-pillar institutional scorecard (led by Balance Sheet & Cash Flow, Options & Positioning). COGT carries a Unified Composite Score of 42.7/100 (HOLD) at $27.44 (N/M Forward P/E, 0.0% operating margin), whereas ZBIO carries 49.4/100 (HOLD) at $27.93 (N/M Forward P/E, -2747.5% operating margin).

  • Technical & Structure Timing Caution: COGT is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 37.3); meanwhile ZBIO is in a Weinstein Distribution regime near a flattening 50-day moving average (RSI 49.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About COGT vs ZBIO
COGT NASDAQ
Cogent Biosciences, Inc. Common Stock
Pharmaceutical Preparations
$27.44
-3.92% 1D
Market Cap $5.0B
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 1.46β · 61% Vol
Unified Composite Score
42.7 / 100 HOLD
Tech 28.0 Fund 49.0 Flow 69.0 Mom 60.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -7.0%), weak momentum, RSI 37
RSI-14: 37.3 · SMA20: $30.83 · SMA50: $31.25
ZBIO NASDAQ Head-to-Head Winner
Zenas BioPharma, Inc. Common Stock
Pharmaceutical Preparations
$27.93
-0.29% 1D
Market Cap $1.9B
TTM Revenue $11M
Forward P/E N/M
Beta / 30D Vol 1.16β · 59% Vol
Unified Composite Score
49.4 / 100 HOLD
Tech 44.0 Fund 53.0 Flow 69.0 Mom 50.0
Weinstein Technical Phase Distribution · Trim / tighten stop
Price near a flattening SMA50 (slope -5.2%) with fading momentum, RSI 49
RSI-14: 49.0 · SMA20: $27.99 · SMA50: $28.48

6-Pillar Scorecard Institutional Category Breakdown (COGT 1 – 2 ZBIO)

Columns: Metric · COGT · ZBIO
1. Valuation Multiples Tie
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue N/M N/M
2. Growth & Scale Tie
Revenue Growth (YoY) -100.0% -100.0%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) N/A $11M
Market Cap $5.0B $1.9B
3. Profitability & Quality COGT
Gross Margin N/A N/A
Operating Margin 0.0% -2747.5%
Net Profit Margin 0.0% 0.0%
Return on Equity (ROE) -99.6% -265.1%
4. Balance Sheet & Cash Flow ZBIO
Cash Generation (TTM) -$326M -$273M
Cash Flow Margin N/A N/A
Net Cash / Leverage $27M Net Debt (0.47x D/E) $177M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning ZBIO
Options Structure Phase BREAKDOWN CONSOLIDATION
Current IV / %ile 61.8% (5th %ile) 103.9% (13th %ile)
Put/Call OI Skew 155.50x (Put-Skewed) N/A
OBV Trend / Tech Phase DISTRIBUTION · Markdown ACCUMULATION · Distribution
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: COGT (3) vs ZBIO (3)
Institutional Metric COGT ZBIO Criterion Row Edge
Market Capitalization
Scale
$5.0B $1.9B Larger Scale COGT
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
-100.0% -100.0% Higher Growth Tie
Operating Margin (TTM)
Profitability
0.0% -2747.5% Higher Margin COGT
Net Profit Margin
Profitability
0.0% 0.0% Higher Margin Tie
Return on Equity (ROE)
Capital Efficiency
-99.6% -265.1% Higher ROE COGT
52-Week Range Position
Momentum
1% ($27–$44) 46% ($14–$45) Stronger Trend ZBIO
Beta / 30D Volatility
Risk Regime
1.46β · 61% Vol 1.16β · 59% Vol Lower Realized Risk ZBIO
Unified Institutional Score
Composite Signal
42.7 / 100 (HOLD) 49.4 / 100 (HOLD) Higher Composite ZBIO
Trailing 12M Revenue (USD)
Operating Scale
N/A $11M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$326M ($27M Net Debt (0.47x D/E)) -$273M ($177M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon ZBIO +19.49 pp
COGT: -7.05% · ZBIO: +12.44%
3M Horizon ZBIO +14.16 pp
COGT: -26.63% · ZBIO: -12.47%
6M Horizon ZBIO +77.67 pp
COGT: -12.5% · ZBIO: +65.17%
1Y Horizon COGT +2.79 pp
COGT: -18.89% · ZBIO: -21.68%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period COGT Revenue ZBIO Revenue COGT Op. Margin ZBIO Op. Margin Margin Leader
FY2017 $10M N/A -312.8% N/A COGT
FY2018 $10M N/A -369.9% N/A COGT
FY2019 $20M N/A -143.0% N/A COGT
FY2020 $10M N/A -1044.3% N/A COGT
FY2023 N/A $50M N/A -74.3% ZBIO
FY2024 N/A $10M N/A -3277.8% ZBIO
FY2025 N/A $10M N/A -3830.6% ZBIO

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
COGT BREAKDOWN
73d in phase · OBV DISTRIBUTION
Current IV 61.8%
IV Percentile 5th %ile
Put/Call OI Skew 155.50x (Put-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow DISTRIBUTION
Exact COGT Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
ZBIO CONSOLIDATION
58d in phase · OBV ACCUMULATION
Current IV 103.9%
IV Percentile 13th %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow ACCUMULATION
Exact ZBIO Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
COGT Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $5.0B market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
ZBIO Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $1.9B market capitalization and -2747.5% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ COGT vs ZBIO Key Questions & Quantitative Answers

As of Nov 16, 2026, Zenas BioPharma, Inc. (ZBIO) is the stronger overall head-to-head candidate over Cogent Biosciences, Inc. (COGT) in the Tradestie Institutional Equity Comparison Engine, winning 3–3 core matrix metrics and 2–1 across our 6-pillar institutional scorecard (led by Balance Sheet & Cash Flow, Options & Positioning). COGT carries a Unified Composite Score of 42.7/100 (HOLD) at $27.44 (N/M Forward P/E, 0.0% operating margin), whereas ZBIO carries 49.4/100 (HOLD) at $27.93 (N/M Forward P/E, -2747.5% operating margin). Technical & Structure Timing Caution: COGT is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 37.3); meanwhile ZBIO is in a Weinstein Distribution regime near a flattening 50-day moving average (RSI 49.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

COGT and ZBIO split Growth & Scale metrics: COGT posts -100.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with ZBIO at -100.0% YoY revenue growth and +0.0% YoY earnings growth on $11M TTM revenue (N/A gross margin, -2747.5% operating margin). Across the 7-period historical trajectory (FY2017 to FY2025), COGT cumulative revenue shifted +0.0% while ZBIO shifted -80.0%. In operating R&D and SG&A reinvestment, COGT deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for ZBIO.

COGT and ZBIO trade at balanced relative valuation multiples. COGT trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas ZBIO trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against COGT (-99.6% ROE) versus ZBIO (-265.1% ROE) capital efficiency.

In options market volatility and institutional positioning, COGT carries 61.8% implied volatility (5th %ile, Compressed (<25th %ile)), a 155.50x (Put-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (1.46β · 61% Vol realized risk). By comparison, ZBIO carries 103.9% implied volatility (13th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, ACCUMULATION on-balance volume, and sits in a CONSOLIDATION options structure phase (1.16β · 59% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.